# EDGAR Filing Document

**Accession Number:** 0001035267
**File Stem:** 0001035267-25-000183
**Filing Date:** 2025-7
**Character Count:** 47958
**Document Hash:** d61e775f92f46ee07df4204ccdf43997
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001035267-25-000183.hdr.sgml**: 20250722

**ACCESSION NUMBER**: 0001035267-25-000183

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250722

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250722

**DATE AS OF CHANGE**: 20250722

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTUITIVE SURGICAL INC
- **CENTRAL INDEX KEY:** 0001035267
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 770416458
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30713
- **FILM NUMBER:** 251140315

**BUSINESS ADDRESS:**
- **STREET 1:** 1020 KIFER ROAD
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94086
- **BUSINESS PHONE:** 4085232100

**MAIL ADDRESS:**
- **STREET 1:** 1020 KIFER ROAD
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94086

?xml version='1.0' encoding='ASCII'? isrg-20250722

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 22, 2025** 

**INTUITIVE SURGICAL, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-30713** | **77-0416458** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

**1020 Kifer Road**

**Sunnyvale, California 94086**

**(Address of Principal Executive Offices) (zip code)**

**Registrant's telephone number, including area code: (408) 523-2100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | ISRG | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.** |

---

On July 22, 2025, Intuitive Surgical, Inc. ("Intuitive") issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release issued by Intuitive Surgical, Inc., dated](q225ex-991earningsrelease.htm) July 22, 2025</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | INTUITIVE SURGICAL, INC. | INTUITIVE SURGICAL, INC. |
| Date: July 22, 2025 | By: | /s/ JAMIE E. SAMATH |
|  |  | *&nbsp;&nbsp;&nbsp;&nbsp; Name:* Jamie E. Samath |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;*Title:* Executive Vice President, Chief Financial Officer |

---

## Ex-99

**Exhibit 99.1**

 <br> <br>Contact: Investor Relations<br>(408) 523-2161

**INTUITIVE ANNOUNCES SECOND QUARTER EARNINGS**

SUNNYVALE, CALIF. July 22, 2025 – Intuitive (the "Company") (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2025.

**Q2 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** The Company placed 395 da Vinci surgical systems, compared with 341 in the second quarter of 2024. The second quarter 2025 da Vinci surgical system placements included 180 da Vinci 5 systems, compared with 70 in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The Company grew its da Vinci surgical system installed base to 10,488 systems as of June 30, 2025, an increase of 14% compared with 9,203 as of June 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Second quarter 2025 revenue of $2.44 billion increased 21% compared with $2.01 billion in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Second quarter 2025 GAAP net income attributable to Intuitive was $658 million, or $1.81 per diluted share, compared with $527 million, or $1.46 per diluted share, in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Second quarter 2025 non-GAAP\* net income attributable to Intuitive was $798 million, or $2.19 per diluted share, compared with $641 million, or $1.78 per diluted share, in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In July 2025, the Company obtained European certification in accordance with the EU MDR for its da Vinci 5 surgical system for adult and pediatric use in minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic surgical procedures, including urologic, gynecologic, and general laparoscopic procedures, excluding the use of force feedback. The Company intends to seek European certification for the use of force feedback in the future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In June 2025, the Company obtained regulatory clearance in Japan for the da Vinci 5 surgical system for use in all surgical specialties and procedures indicated for da Vinci Xi, except for cardiac indications.

**Q2 Financial Summary**

Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on a GAAP and non-GAAP\* basis. The non-GAAP\* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.

Second quarter 2025 revenue was $2.44 billion, an increase of 21% compared with $2.01 billion in the second quarter of 2024. The higher second quarter revenue was driven by growth in da Vinci procedure volume, higher da Vinci system placements, and an increase in the installed base of systems.

Second quarter 2025 instruments and accessories revenue increased by 18% to $1.47 billion, compared with $1.24 billion in the second quarter of 2024. The increase in instruments and accessories revenue was primarily driven by approximately 17% growth in da Vinci procedure volume and approximately 52% growth in Ion procedure volume.

Second quarter 2025 systems revenue was $575 million, compared with $448 million in the second quarter of 2024. The Company placed 395 da Vinci surgical systems, of which 180 were da Vinci 5 systems, in the second quarter of 2025, compared with 341 systems, of which 70 were da Vinci 5 systems, in the second quarter of 2024. The second quarter 2025 da Vinci surgical system placements included 193 systems placed under operating lease arrangements, of which 124 systems were placed under usage-based operating lease arrangements, compared with 175 systems placed under operating lease arrangements, of which 92 systems were placed under usage-based operating lease arrangements in the second quarter of 2024.

Second quarter 2025 GAAP income from operations increased to $743 million, compared with $567 million in the second quarter of 2024. Second quarter 2025 GAAP income from operations included share-based compensation expense of $200 million, compared with $176 million in the second quarter of 2024. Second quarter 2025 non-GAAP\* income from operations increased to $947 million, compared with $754 million in the second quarter of 2024.

Page 1 of 9

------

Second quarter 2025 GAAP net income attributable to Intuitive Surgical, Inc. was $658 million, or $1.81 per diluted share, compared with $527 million, or $1.46 per diluted share, in the second quarter of 2024. Second quarter 2025 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of $33 million, or $0.09 per diluted share, compared with $36 million, or $0.10 per diluted share, in the second quarter of 2024.

Second quarter 2025 non-GAAP\* net income attributable to Intuitive Surgical, Inc. was $798 million, or $2.19 per diluted share, compared with $641 million, or $1.78 per diluted share, in the second quarter of 2024.

The Company ended the second quarter of 2025 with $9.53 billion in cash, cash equivalents, and investments, an increase of $431 million during the quarter, primarily driven by cash generated from operations, partially offset by cash used in repurchases of common stock and capital expenditures.

"We're pleased with our solid performance this quarter, highlighted by continued customer adoption of our newer and existing platforms, including da Vinci 5," stated Dave Rosa, Intuitive CEO. "We are committed to advancing care, and helping our customers provide better patient outcomes, better patient and care team experiences, broadening access to care and decreasing the total cost of care."

**2025 Financial Outlook**

The Company expects the following results for the full year of 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Worldwide da Vinci procedure growth of approximately 15.5% to 17% in 2025, compared to 17% in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP\* gross profit margin to be within a range of 66% and 67% of revenue in 2025, compared to 69.1% in 2024. This range includes an estimated impact from tariffs of 1.0% of revenue, plus or minus 20 basis points.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP\* operating expense growth of 10% to 14% in 2025, compared to 10% in 2024.

The updated range for expected non-GAAP\* gross profit margin reflects the Company's estimates of the adverse impact from tariffs that are currently in effect as of the time of this press release and assumes such tariffs remain in place. Should additional tariffs be implemented or existing tariffs be modified, the additional impact on the Company's financial results in 2025, including the change in expected non-GAAP\* gross profit margin, could be material. The ultimate effect of tariffs will depend on various factors, including the proportion of components procured and finished goods manufactured outside of the United States and the amount, scope, nature, and timing of the tariffs.

The 2025 financial outlook provided above includes forward-looking, non-GAAP financial measures, which management uses in measuring performance. We do not provide a reconciliation of non-GAAP outlook measures to corresponding GAAP measures on a forward-looking basis, because we are unable to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including but not limited to legal proceedings, without unreasonable efforts. These items are uncertain, depend on various factors, and could be material to Intuitive's results computed in accordance with GAAP. For additional information regarding the nature of these items, refer to the reconciliations of historical GAAP to non-GAAP measures included elsewhere in this release.

Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at *https://isrg.gcs-web.com/*.

**Webcast and Conference Call Information**

Intuitive will hold a teleconference at 1:30 p.m. PDT today to discuss the second quarter 2025 financial results. The call will be webcast live and can be accessed on Intuitive's website at *www.intuitive.com*. For those individuals planning to participate on the call, registration can be completed online at *https://register-conf.media-server.com/register/BIce4ff910277b4e438ebb356ec90815a5* to receive dial-in details and an individual pin. The webcast replay of the call will be made available on our website at *www.intuitive.com* within 24 hours after the end of the live teleconference and will be accessible for at least 30 days.

**About Intuitive**

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical systems and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most.

Page 2 of 9

------

Product and brand names/logos are trademarks or registered trademarks of Intuitive or their respective owner. See *www.intuitive.com/trademarks*.

For more information, please visit the Company's website at *www.intuitive.com*.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to expectations concerning matters that are not historical facts. Statements using words such as "estimates," "projects," "believes," "anticipates," "plans," "expects," "intends," "may," "will," "could," "should," "would," "targeted," and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of the Company's management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to the following: statements related to future results of operations, including expected procedure growth in 2025, expected non-GAAP gross profit margins in 2025, and expected non-GAAP operating expense growth in 2025; future financial position; the adoption by customers of the Company's products; and the Company's commitment to advancing care, helping customers provide better patient outcomes and better patient and care team experiences, broadening access to care, and decreasing the total cost of care. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: the overall macroeconomic environment, which may impact customer spending and the Company's costs, including tariffs, the levels of inflation, and interest rates; the conflict between Ukraine and Russia; conflicts in the Middle East; disruption to the Company's supply chain, including difficulties in obtaining a sufficient supply of materials; curtailed or delayed capital spending by hospitals; the impact of global and regional economic and credit market conditions on healthcare spending; delays in obtaining new product approvals, clearances, or certifications from the United States ("U.S.") Food and Drug Administration ("FDA"), comparable regulatory authorities, or notified bodies; the risk of the Company's inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and customer acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company's completion of and ability to successfully integrate acquisitions; intellectual property positions and litigation; risks associated with the Company's operations and any expansion outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company's reliance on sole- and single-sourced suppliers; the results of legal proceedings to which the Company is or may become a party; adverse publicity regarding the Company and the safety of the Company's products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements (including changes to tariffs imposed by the U.S. on imports from various countries, including Mexico, where the Company currently manufactures a significant majority of our instruments and accessories, Germany, where the Company currently manufactures a majority of our endoscopes, and China, where the Company currently imports certain materials); and other risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company's other filings with the Securities and Exchange Commission. The Company's actual results may differ materially and adversely from those expressed in any forward-looking statement, and the Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

Page 3 of 9

------

**\*About Non-GAAP Financial Measures**

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., and non-GAAP net income per diluted share attributable to Intuitive Surgical, Inc. ("EPS"). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as amortization of intangible assets, share-based compensation ("SBC") and long-term incentive plan expenses, and other special items. Long-term incentive plan expense relates to phantom share awards granted in China by the Company's Intuitive-Fosun joint venture to its employees that vest over four years and can remain outstanding for seven to ten years. These awards are valued based on certain key performance metrics. Accordingly, they are subject to significant volatility based on the performance of these metrics and are not tied to performance of the Company's business within the period. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to its historical performance. The Company believes these non-GAAP financial measures are useful to investors, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company's business.

*Non-GAAP gross profit*. The Company defines non-GAAP gross profit as gross profit, excluding SBC and long-term incentive plan expenses and amortization of intangible assets.

*Non-GAAP income from operations*. The Company defines non-GAAP income from operations as income from operations, excluding SBC and long-term incentive plan expenses, amortization of intangible assets, and litigation charges.

*Non-GAAP net income attributable to Intuitive Surgical, Inc. and EPS*. The Company defines non-GAAP net income as net income attributable to Intuitive Surgical, Inc., excluding SBC and long-term incentive plan expenses, amortization of intangible assets, litigation charges, gains or losses on strategic investments, tax adjustments, including the excess tax benefits or deficiencies associated with SBC arrangements and the net tax effects related to intra-entity transfers of non-inventory assets, and adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects. The Company excludes the excess tax benefits or deficiencies associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the ongoing results of its core operations. The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that these non-GAAP adjustments had on the Company's operating results. The Company's calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. The Company defines non-GAAP EPS as non-GAAP net income attributable to Intuitive Surgical, Inc. divided by diluted shares outstanding, which are calculated as GAAP weighted-average outstanding shares plus dilutive potential shares outstanding during the period.

There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., and non-GAAP EPS exclude items such as SBC and long-term incentive plan expenses, amortization of intangible assets, excess tax benefits or deficiencies associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfer of non-inventory assets, which are primarily recurring items. SBC expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company's business. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS and evaluating non-GAAP net income

Page 4 of 9

------

attributable to Intuitive Surgical, Inc. and non-GAAP EPS together with net income attributable to Intuitive Surgical, Inc. and net income per share attributable to Intuitive Surgical, Inc. calculated in accordance with GAAP.

Page 5 of 9

------

**INTUITIVE SURGICAL, INC.** 

**UNAUDITED QUARTERLY CONDENSED CONSOLIDATED STATEMENTS OF INCOME** 

**(IN MILLIONS, EXCEPT PER SHARE DATA)**

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **June 30,<br>2025** | **March 31,<br>2025** | **June 30,<br>2024** |
| Revenue: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Instruments and accessories | $1474.1 | $1367.7 | $1244.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Systems | 574.7 | 522.7 | 448.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Services | 391.2 | 363.0 | 317.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 2440.0 | 2253.4 | 2009.9 |
| Cost of revenue: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product | 686.2 | 670.7 | 539.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Service | 135.9 | 125.0 | 97.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue | 822.1 | 795.7 | 637.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 1617.9 | 1457.7 | 1372.7 |
| Operating expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 561.2 | 563.4 | 525.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 313.3 | 316.2 | 280.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 874.5 | 879.6 | 805.4 |
| Income from operations <sup>(1)</sup> | 743.4 | 578.1 | 567.3 |
| Interest and other income (expense), net | 88.7 | 90.4 | 87.2 |
| Income before taxes | 832.1 | 668.5 | 654.5 |
| Income tax expense (benefit) <sup>(2)</sup> | 167.9 | (35.2) | 123.0 |
| Net income | 664.2 | 703.7 | 531.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: net income attributable to noncontrolling interest in joint venture | 5.8 | 5.3 | 4.6 |
| Net income attributable to Intuitive Surgical, Inc. | $658.4 | $698.4 | $526.9 |
| **Net income per share attributable to Intuitive Surgical, Inc.:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $1.84 | $1.95 | $1.48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted <sup>(3)</sup> | $1.81 | $1.92 | $1.46 |
| **Weighted average shares outstanding:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 358.5 | 357.5 | 355.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 364.1 | 364.6 | 361.0 |
| <sup>(1)</sup> Income from operations includes the effect of the following items: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | $(3.2) | $(3.4) | $(5.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Expensed IP charged to R&D | $(1.6) | $(5.1) | $(0.2) |
| <sup>(2)</sup> Income tax expense (benefit) includes the effect of the following items: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Excess tax benefits related to share-based compensation arrangements | $(32.9) | $(145.4) | $(35.7) |
| <sup>(3)</sup> Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets, net of tax | $(0.01) | $(0.01) | $(0.01) |
| &nbsp;&nbsp;&nbsp;&nbsp;Expensed IP charged to R&D, net of tax | $— | $(0.01) | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Excess tax benefits related to share-based compensation arrangements | $0.09 | $0.40 | $0.10 |

---

Page 6 of 9

------

**INTUITIVE SURGICAL, INC.** 

**UNAUDITED SIX MONTHS ENDED CONDENSED CONSOLIDATED STATEMENTS OF INCOME** 

**(IN MILLIONS, EXCEPT PER SHARE DATA)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **June 30,** | **June 30,** |
| | **2025** | **2024** |
| Revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Instruments and accessories | $2841.8 | $2403.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Systems | 1097.4 | 866.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Services | 754.2 | 630.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 4693.4 | 3900.5 |
| Cost of revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product | 1356.9 | 1093.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Service | 260.9 | 188.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue | 1617.8 | 1282.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 3075.6 | 2618.1 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 1124.6 | 1016.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 629.5 | 564.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 1754.1 | 1581.4 |
| Income from operations <sup>(1)</sup> | 1321.5 | 1036.7 |
| Interest and other income, net | 179.1 | 156.3 |
| Income before taxes | 1500.6 | 1193.0 |
| Income tax expense <sup>(2)</sup> | 132.7 | 114.1 |
| Net income | 1367.9 | 1078.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: net income attributable to noncontrolling interest in joint venture | 11.1 | 7.1 |
| Net income attributable to Intuitive Surgical, Inc. | $1356.8 | $1071.8 |
| **Net income per share attributable to Intuitive Surgical, Inc.:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $3.79 | $3.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted <sup>(3)</sup> | $3.72 | $2.97 |
| **Weighted average shares outstanding:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 358.0 | 354.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 364.4 | 360.8 |
| <sup>(1)</sup> Income from operations includes the effect of the following items: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | $(6.6) | $(10.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Expensed IP charged to R&D | $(6.7) | $(0.2) |
| <sup>(2)</sup> Income tax expense includes the effect of the following items: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Excess tax benefits related to share-based compensation arrangements | $(178.3) | $(146.8) |
| <sup>(3)</sup> Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets, net of tax | $(0.01) | $(0.02) |
| &nbsp;&nbsp;&nbsp;&nbsp;Expensed IP charged to R&D, net of tax | $(0.01) | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Excess tax benefits related to share-based compensation arrangements | $0.49 | $0.41 |

---

Page 7 of 9

------

**INTUITIVE SURGICAL, INC.** 

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS** 

**(IN MILLIONS)**

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| Cash, cash equivalents, and investments | $9532.5 | $8832.4 |
| Accounts receivable, net | 1269.2 | 1225.4 |
| Inventory | 1667.0 | 1487.2 |
| Property, plant, and equipment, net | 4985.3 | 4646.6 |
| Goodwill | 348.7 | 347.5 |
| Deferred tax assets | 1070.3 | 1045.1 |
| Other assets | 1290.2 | 1159.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $20163.2 | $18743.2 |
| Accounts payable and other liabilities | $1638.4 | $1690.7 |
| Deferred revenue | 571.7 | 522.9 |
| Total liabilities | 2210.1 | 2213.6 |
| Stockholders' equity | 17953.1 | 16529.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $20163.2 | $18743.2 |

---

Page 8 of 9

------

**INTUITIVE SURGICAL, INC.**

**UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES**

**(IN MILLIONS, EXCEPT PER SHARE DATA)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **June 30,<br>2025** | **March 31,<br>2025** | **June 30,<br>2024** | **June 30,<br>2025** | **June 30,<br>2024** |
| **GAAP gross profit** | $1617.9 | $1457.7 | $1372.7 | $3075.6 | $2618.1 |
| Share-based compensation expense | 36.6 | 36.2 | 29.7 | 72.8 | 58.8 |
| Long-term incentive plan expense | 0.1 | 0.3 | 0.1 | 0.4 | 0.4 |
| Amortization of intangible assets | 2.5 | 2.4 | 3.7 | 4.9 | 7.5 |
| **Non-GAAP gross profit** | $1657.1 | $1496.6 | $1406.2 | $3153.7 | $2684.8 |
| **GAAP income from operations** | $743.4 | $578.1 | $567.3 | $1321.5 | $1036.7 |
| Share-based compensation expense | 196.2 | 185.2 | 173.6 | 381.4 | 326.9 |
| Long-term incentive plan expense | 0.3 | 0.8 | 1.0 | 1.1 | 3.2 |
| Amortization of intangible assets | 3.2 | 3.4 | 5.0 | 6.6 | 10.1 |
| Litigation charges | 3.5 |  | 7.2 | 3.5 | 7.2 |
| **Non-GAAP income from operations** | $946.6 | $767.5 | $754.1 | $1714.1 | $1384.1 |
| **GAAP net income attributable to Intuitive Surgical, Inc.** | $658.4 | $698.4 | $526.9 | $1356.8 | $1071.8 |
| Share-based compensation expense | 196.2 | 185.2 | 173.6 | 381.4 | 326.9 |
| Long-term incentive plan expense | 0.3 | 0.8 | 1.0 | 1.1 | 3.2 |
| Amortization of intangible assets | 3.2 | 3.4 | 5.0 | 6.6 | 10.1 |
| Litigation charges | 3.5 |  | 7.2 | 3.5 | 7.2 |
| (Gains) losses on strategic investments | 4.4 | 0.6 | (7.8) | 5.0 | (4.4) |
| Tax adjustments <sup>(1)</sup> | (67.8) | (226.6) | (64.5) | (294.4) | (231.5) |
| Adjustments attributable to noncontrolling interest in joint venture | (0.3) | (0.3) | (0.4) | (0.6) | (1.2) |
| **Non-GAAP net income attributable to Intuitive Surgical, Inc.** | $797.9 | $661.5 | $641.0 | $1459.4 | $1182.1 |
| **GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted** | $1.81 | $1.92 | $1.46 | $3.72 | $2.97 |
| Share-based compensation expense | 0.54 | 0.50 | 0.48 | 1.05 | 0.90 |
| Long-term incentive plan expense |  |  |  |  | 0.01 |
| Amortization of intangible assets | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 |
| Litigation charges | 0.01 |  | 0.02 | 0.01 | 0.02 |
| (Gains) losses on strategic investments | 0.01 |  | (0.02) | 0.01 | (0.01) |
| Tax adjustments <sup>(1)</sup> | (0.19) | (0.62) | (0.18) | (0.81) | (0.64) |
| Adjustments attributable to noncontrolling interest in joint venture |  |  |  |  |  |
| **Non-GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted** | $2.19 | $1.81 | $1.78 | $4.00 | $3.28 |
| <sup>(1)</sup> For the three months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(32.9) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(45.6) million, or $(0.13) per diluted share. For the three months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(35.7) million, or $(0.10) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(39.0) million, or $(0.11) per diluted share. | <sup>(1)</sup> For the three months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(32.9) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(45.6) million, or $(0.13) per diluted share. For the three months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(35.7) million, or $(0.10) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(39.0) million, or $(0.11) per diluted share. | <sup>(1)</sup> For the three months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(32.9) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(45.6) million, or $(0.13) per diluted share. For the three months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(35.7) million, or $(0.10) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(39.0) million, or $(0.11) per diluted share. | <sup>(1)</sup> For the three months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(32.9) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(45.6) million, or $(0.13) per diluted share. For the three months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(35.7) million, or $(0.10) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(39.0) million, or $(0.11) per diluted share. | <sup>(1)</sup> For the three months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(32.9) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(45.6) million, or $(0.13) per diluted share. For the three months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(35.7) million, or $(0.10) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(39.0) million, or $(0.11) per diluted share. | <sup>(1)</sup> For the three months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(32.9) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(45.6) million, or $(0.13) per diluted share. For the three months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(35.7) million, or $(0.10) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(39.0) million, or $(0.11) per diluted share. |
| For the six months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(178.3) million, or $(0.49) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(137.5) million, or $(0.38) per diluted share. For the six months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(146.8) million, or $(0.41) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $20.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(105.1) million, or $(0.29) per diluted share. | For the six months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(178.3) million, or $(0.49) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(137.5) million, or $(0.38) per diluted share. For the six months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(146.8) million, or $(0.41) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $20.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(105.1) million, or $(0.29) per diluted share. | For the six months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(178.3) million, or $(0.49) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(137.5) million, or $(0.38) per diluted share. For the six months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(146.8) million, or $(0.41) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $20.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(105.1) million, or $(0.29) per diluted share. | For the six months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(178.3) million, or $(0.49) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(137.5) million, or $(0.38) per diluted share. For the six months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(146.8) million, or $(0.41) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $20.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(105.1) million, or $(0.29) per diluted share. | For the six months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(178.3) million, or $(0.49) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(137.5) million, or $(0.38) per diluted share. For the six months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(146.8) million, or $(0.41) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $20.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(105.1) million, or $(0.29) per diluted share. | For the six months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(178.3) million, or $(0.49) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(137.5) million, or $(0.38) per diluted share. For the six months ended June 30, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(146.8) million, or $(0.41) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $20.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(105.1) million, or $(0.29) per diluted share. |

---

Page 9 of 9